Based on in vitro, animal and human evidence, the Mischel laboratory has established that the SSRI drug fluoxetine is an effective therapy for glioblastoma. The goal of this project is to introduce a superior fluoxetine analog into clinical trials for this highly lethal form of cancer.

For more information about this project, see the team’s recent publication (PMID: 34731610).